Q-omics provides the consensus-scored MTCYBP16 profile across patient tissues and cancer cell-line models. MTCYBP16 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MTCYBP16 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, MTCYBP16 RNA expression shows 7,148 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, KIRC, and ACC as cancer lineages where MTCYBP16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCYBP16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCYBP16 survival associations across molecular data types. MTCYBP16 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCYBP16 RNA expression–survival associations across cancer types. High MTCYBP16 expression shows unfavorable associations in LUAD and UCS, but favorable associations in BLCA, LUSC, ACC and KIRP. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for MTCYBP16 RNA expression.
This table summarizes MTCYBP16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MTCYBP16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCYBP16 shows lower tumor expression in KIRC and higher tumor expression in COAD, KICH and UCEC. The KIRC box plot shows higher MTCYBP16 RNA expression in normal versus tumor tissue (log2 FC = −0.072, t-test p < 0.001).
This table shows molecular features associated with MTCYBP16 in patient tissues and cancer cell lines. In patient samples, MTCYBP16 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
